[{"orgOrder":0,"company":"Dalton Pharma Services","sponsor":"Health Canada","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Dalton Pharma Services","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Dalton Pharma Services \/ Health Canada","highestDevelopmentStatusID":"12","companyTruncated":"Dalton Pharma Services \/ Health Canada"},{"orgOrder":0,"company":"Dalton Pharma Services","sponsor":"VIDO-InterVac","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"COVID-19 vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Dalton Pharma Services","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Dalton Pharma Services \/ VIDO-InterVac","highestDevelopmentStatusID":"1","companyTruncated":"Dalton Pharma Services \/ VIDO-InterVac"},{"orgOrder":0,"company":"Dalton Pharma Services","sponsor":"Algernon Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Dalton Pharma Services","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Dalton Pharma Services \/ Algernon Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Dalton Pharma Services \/ Algernon Pharmaceuticals"}]

Find Clinical Drug Pipeline Developments & Deals by Dalton Pharma Services

Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Algernon Pharmaceuticals has awarded the contract to manufacture the active pharmaceutical ingredient and finished product for its formulation of AP-188 (“N,N-Dimethyltryptamine or DMT”), to Canadian-based Dalton Pharma Services.

                          Brand Name : AP-188

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          February 19, 2021

                          Lead Product(s) : Dimethyltryptamine

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Algernon Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Under this Partnership, Dalton will be responsible for the formulation and fill/finish of VIDO-InterVac’s COVID-19 vaccine to be used in early Phase clinical trials from Dalton`s cGMP biopharmaceutical facility in Toronto, Canada.

                          Brand Name : Undisclosed

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          July 28, 2020

                          Lead Product(s) : COVID-19 vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : VIDO-InterVac

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          03

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Dalton receives the license amendment from Health Canada under Cannabis regulations enabling transfer of finished cGMP cannabis products to licensed dealers.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          January 15, 2020

                          Lead Product(s) : Cannabidiol

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved

                          Sponsor : Health Canada

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank